DIZE (Dexamethasone, Idarubicin, and Continuous Infusion of Ifosfamide and Etoposide): an Effective and Well-Tolerated New Regimen for Patients with Relapsed Lymphoma
- 1 January 1998
- journal article
- clinical trial
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 31 (3-4), 359-366
- https://doi.org/10.3109/10428199809059229
Abstract
We performed a phase II study of dexamethasone, ifosfamide, idarubicin and etoposide (DIZE) in patients with relapsed or refractory Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL). The regimen consisted of dexamethasone (20 mg i.v. days 1-4), idarubicin (8 mg/m2 i.v. days 1+2), continuous infusion (c.i.) of ifosfamide (1,000 mg/m2 days 1-4), and c.i. etoposide (60 mg/m2 days 1-4). G-CSF (5 µ g/kg) was used to support neutrophil recovery from day 5. In older patients (> 60 years) the dosage of idarubicin and ifosfamide was reduced to 75% in the initial cycle. Fourty six patients (pts) were treated with a total of 131 cycles. Sixteen pts were primary resistant and 30 were relapsed. Median age was 54.3 years (range 22-75). The median number of different prior chemotherapies was 1.7 (range 1 to 5). 31/46 (67.4%) pts had advanced disease (stage III or IV); 19/46 had B symptoms. of 43 evaluable pts the response rate was 58.1% including 11 complete remissions (CR) and 14 partial remissions (PR). Mean duration of response was 8 months (1-30+). DIZE was more effective in relapsed than in refractory high-grade NHL (74% vs 16.6%; p < 0.001). Of four heavily pretreated pts with HL, one obtained CR and two PR (response rate 75%). Myelosuppression was generally moderate with a mean duration of leukocytopenia < 1<, 000/µ1 of 2.5 days (range 0-18) and of thrombocytopenia < 25,000/µ1 1.5 days (range 0-17). One patient died of uncontrollable infection in treatment related neutropenia. No other serious toxicities apart from alopecia were observed. We conclude that DIZE is safe and effective in heavily pretreated pts with relapsed lymphoma. The continuous infusion of cytostatic drugs such as that used in the new DIZE protocol might reduce hematotoxicity.Keywords
This publication has 18 references indexed in Scilit:
- A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's LymphomaLeukemia & Lymphoma, 1997
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphomaEuropean Journal of Haematology, 1995
- Chronic Lymphocytic Leukemia with an Interfollicular Architecture: Avoiding Diagnostic Confusion with Monocytoid B-cell LymphomaLeukemia & Lymphoma, 1995
- Dice (Dexamethasone, Ifosfamide, Cisplatin, Etoposide) as Salvage Therapy in Non-Hodgkin's LymphomasLeukemia & Lymphoma, 1995
- EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1993
- Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.Journal of Clinical Oncology, 1993
- Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphomaCancer, 1989
- Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)Blood, 1988
- IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapyBlood, 1982